Comparing the current results to its competitors, Neuropace Inc reported Revenue decrease in the 1 quarter 2026 year on year by -1.32 %, despite the revenue increase by the most of its competitors of 7.3 %, recorded in the same quarter.
Neuropace Inc 's Comment on Competition and Industry Peers
The company operates in the neuromodulation device market for treating drug-resistant focal epilepsy patients who are not suitable candidates for or decline ablative or resective surgery. Its primary competitors are LivaNova plc, manufacturer of the VNS System, and Medtronic plc, manufacturer of the DBS System. These competitors are larger, well-capitalized firms with extensive resources, including established sales and marketing programs, broad product portfolios, long operating histories, established relationships with healthcare professionals, manufacturing scale, financial capacity for product development, and brand recognition. The company positions its RNS System based on its tolerability, efficacy, continuous brain data access, and ability to address unmet needs in epilepsy care. It also competes with these companies for qualified personnel. The company faces challenges related to patent protection and intellectual property rights, as competitors may develop systems outside its patent coverage. Its commercial success depends on securing and enforcing adequate patent claims and avoiding infringement of third-party intellectual property rights.
Boston Scientific Corporations business model centers on creating innovative medical devices for diverse specialties, aimed at addressing unmet medical needs and enhancing patient outcomes. The company sells its products to healthcare professionals and hospitals globally, supported by robust sales and distribution networks. It prioritizes research and development to continually introduce new technologies and solutions.
Clearpoint Neuro Inc's business model revolves around providing advanced deep brain stimulation (DBS) solutions for the treatment of neurological disorders. It focuses on developing and commercializing innovative medical devices, software, and services that enable precise and accurate targeting for electrode placement during neurosurgical procedures.
Electrocore Inc operates on a business model that focuses on developing and commercializing innovative neuromodulation therapies. They utilize non-invasive vagus nerve stimulation (nVNS) to offer patients drug-free solutions for various medical conditions. The company's approach involves leveraging their understanding of the human body's electrochemical signaling system to provide targeted and effective treatments across multiple therapeutic areas.
Inspire Medical Systems Inc operates on a direct-to-patient business model, focused on developing and commercializing innovative medical devices for patients suffering from sleep apnea. The company's business model revolves around providing a unique therapy solution through the development of its proprietary Inspire therapy system, which includes a surgically implanted device that stimulates the upper airway during sleep. By targeting both physicians and patients, Inspire Medical Systems aims to improve clinical outcomes and bring relief to those with unmet needs in the field of sleep apnea treatment.
Livanova Plc is a global medical technology company that focuses on developing and delivering innovative solutions for patients with cardiovascular diseases and neuropsychiatric disorders. Through their diverse portfolio, they offer products and therapies that encompass surgical heart valves, cardiac rhythm management, and neuromodulation. Livanova adopts a patient-centric approach, collaborating with healthcare professionals to improve patient outcomes and enhance quality of life.
Sources:
Neuropace Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Neuropace Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
